Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Treatment received by RA and control patients after myocardial infarction

From: Rheumatoid arthritis patients receive less frequent acute reperfusion and secondary prevention therapy after myocardial infarction compared with the general population

  RA (n= 90) Controls (n= 90)     
  n % n % Unadjusted ORa
(95% CI)
Adjusted ORb
(95% CI)
Acute reperfusionc 14 16 33 37 0.27 (0.10-0.64) 0.21 (0.07-0.62)
Thrombolysis 8 9 22 24 0.30 (0.10-0.77) 0.33 (0.11-0.96)
PCI 10 11 30 33 0.20 (0.06-0.53) 0.23 (0.09-0.63)
PCA 39 43 52 58 0.41 (0.16-0.92) 0.54 (0.23-1.25)
CABGS 11 12 17 19 0.57 (0.21-1.46) 0.67 (0.27-1.65)
  1. CABGS, coronary artery bypass graft surgery; CI, confidence interval; OR, odds ratio; PCA, percutaneous coronary angiography; PCI, percutaneous coronary intervention (angioplasty ± insertion of stent); RA, rheumatoid arthritis. aMcNemar χ2 test. bConditional logistic regression, adjusting for type of MI (STEMI or NSTEMI), presence of prior MI, and clinical setting of MI. cAcute reperfusion defined as the administration of thrombolysis or PCI within 12 hours of the first symptom of MI.